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Summary
Background: Left ventricular (LV) diastolic dysfunction is related to increased cardiac
sympathetic activity. We investigated the effect of cilnidipine, an L/N-type calcium
channel blocker, on LV diastolic function and cardiac sympathetic activity in patients
with hypertensive heart disease (HHD) using radionuclide myocardial imaging.
Methods and results: Thirty-two frame electrocardiography (ECG) -gated 99mTc-
sestamibi (MIBI) myocardial single photon emission computed tomography (SPECT),
and 123I-metaiodobenzylguanidine (MIBG) imaging were performed before and 6
months after drug administration in 32 outpatients with HHD. Sixteen of the patients
were treated with cilnidipine and the other 16 were treated with nifedipine retard.
The parameters for assessing LV diastolic function evaluated using ECG-gated 99mTc-
MIBI SPECT were peak ﬁlling rate (PFR), ﬁrst-third ﬁlling rate (1/3FR), and time to
peak ﬁlling (TPF). Cardiac sympathetic activity was assessed as early and delayed
heart to mediastinum (H/M) ratios and a washout rate (WR), using 123I-MIBG imaging.
The PFR and 1/3FR signiﬁcantly increased after 6 months of treatment with cilnidip-
ine (p < 0.05 for both), but did not with nifedipine retard. The H/M ratios signiﬁcantly
increased (p < 0.05 for both) in conjunction with a decreased WR (p < 0.05) in the
cilnidipine group. Moreover, a signiﬁcant positive correlation was seen between the
rate of change in PFR and the rate of change in early and delayed H/M ratios in
the cilnidipine group (p < 0.05 for both). The same results were obtained for the
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Cardioprotective effect of a
thetic overactivity via blockade of N-type calcium channels and improves LV diastolic
function in patients with HHD.
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not received any antihypertensive therapy. All the
patients had LV hypertrophy [inter-ventricular sep-
tal thickness (IVSt) and/or posterior wall thickness© 2009 Japanese Colleg
reserved.
ntroduction
eft ventricular (LV) hypertrophy has been identi-
ed as a risk factor for cardiac and cerebrovascular
orbidity and mortality in patients with hyperten-
ive heart disease (HHD) [1,2]. Impaired LV diastolic
unction and increased LV mass are common ﬁnd-
ngs in hypertensive patients and may occur very
arly in the development of essential hypertension
3—5]. Several studies have investigated the mech-
nisms underlying LV hypertrophy, initially with a
rimary focus on hemodynamic factors such as ele-
ated blood pressure (BP) and afterload [6]. There
as been increasing evidence for a considerable
ontribution of neurohumoral factors such as the
enin-angiotensin system and the sympathetic ner-
ous system on LV hypertrophy [7—9]. Because a
egression of LV mass with antihypertensive drugs
ecreases the risk of future cardiovascular compli-
ations, the goal of antihypertensive therapy is to
oth lower BP and intervene in these pathophys-
ologic factors that promote LV hypertrophy and
iastolic dysfunction.
Calcium channel blockers (CCBs) are now widely
sed for the treatment of hypertension. Like
ngiotensin-converting enzyme (ACE) inhibitors or
ngiotensin receptor blockers (ARBs), long-acting
CBs have been reported to reduce LV mass (LVM)
nd improve diastolic function [10,11]. One of
everal CCB types, cilnidipine is a unique dihydropy-
idine CCB, which blocks not only L-type calcium
hannels in vascular smooth muscle, but also
-type calcium channels in sympathetic nerve ter-
inals [12,13]. N-type voltage-dependent calcium
hannels play an important role in sympathetic
eurotransmission, and regulate the release of
orepinephrine (NE) from sympathetic nerve ter-
inals [14]. It has been reported that once-daily
dministration of cilnidipine contributes to an
mprovement in LV hypertrophy and diastolic func-
ion in hypertensive patients through suppression
f sympathetic overactivity, as seen with M-
ode and pulsed Doppler echocardiography (UCG)15,16].
Numerous echocardiographic systolic and dias-
olic parameters, such as LV ejection fraction
LVEF) and diastolic transmitral ﬂow have been
(
t
ﬁ
pCardiology. Published by Elsevier Ireland Ltd. All rights
roposed to evaluate LV function. However, some
ethodological limitations of these parameters
ave been raised, especially with regard to diastolic
unction assessment [17,18]. With radionuclide
maging, studies using electrocardiography (ECG)-
ated 99mTc-sestamibi (MIBI) myocardial single
hoton emission computed tomography (SPECT)
rovided accurate and reproducible information on
V function [19—21]. Moreover, myocardial imaging
ith 123I-metaiodobenzylguanidine (MIBG) provided
nformation that reﬂects cardiac sympathetic nerve
ctivity [22,23].
Several studies have separately investigated the
ffects of cilnidipine on LV diastolic function and
ympathetic activity, but to the best of our knowl-
dge, none has simultaneously measured these two
actors and assessed their relationship. The present
tudy assessed the effects of cilnidipine on LV dias-
olic function and cardiac sympathetic activity in
atients with HHD, using 99mTc-MIBI and 123I-MIBG
yocardial imaging. Furthermore, we ascertained
hether the improvements in LV diastolic function
re associated with the changes to cardiac sympa-
hetic activity.
ethods
ubjects
he present study was conducted prospectively
n 32 patients with essential hypertension (23
ales and 9 females; mean age: 67 years; range:
8—79 years) who visited outpatient clinics of our
niversity hospital and Akita City Hospital from
eptember 2005 to October 2006, and whose morn-
ng BP at home was ≥135mmHg and/or ≥85mmHg.
wenty of these patients were currently taking anti-
ypertensive medication other than a CCB, and
he remaining 12 were newly diagnosed and hadn L/N-type Ca channel blocker 263
relationship between the rate of change in 1/3FR and the rate of change in H/M ratios
(p < 0.05 for both). However, no such relationship was seen in the nifedipine group.
Conclusion: These data indicate that cilnidipine seems to suppress cardiac sympa-PWt) ≥12mm at end diastole] with normal sys-
olic function (LVEF ≥50%) and impaired diastolic
lling determined using UCG. From the results of
hysical and laboratory examinations, as well as
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routine UCG, patients with secondary hyperten-
sion, chronic kidney disease, major cardiovascular
complications involving cardiomyopathies, unsta-
ble angina, myocardial infarction, congenital heart
disease, and signiﬁcant valvular heart disease were
excluded from the study.
Study protocol
Written informed consent was obtained from all
study participants and the study protocol was
approved by the Ethics Committees of Akita Uni-
versity School of Medicine and Akita City Hospital.
Patients were asked to measure and record their
home BP and heart rate (HR) once every morning in
the seated position before breakfast within 1 h after
waking up, using an automated cuff device. They
were randomly allocated to two groups to receive
cilnidipine or nifedipine retard for 6 months. The
cilnidipine group was started on 5—10mg of cilni-
dipine just after breakfast, increasing by 5mg up
to 20mg with an interval of 4 weeks. The nifedip-
ine group was started on 10—20mg of nifedipine
retard once daily after breakfast, increasing by
10mg up to 40mg. The titration for both drugs
was performed, if the level of morning BP at home
remained high (i.e., systolic BP ≥135mmHg or dias-
tolic BP ≥85mmHg). For patients currently given
antihypertensive medication, cilnidipine or nifedip-
ine retard was added to their current prescription.
The doses of other antihypertensive drugs were not
changed upon addition of their CCB. The newly
diagnosed patients were placed on monotherapy
with cilnidipine or nifedipine retard.
During the study period, patients were asked
to visit hospital every 4 weeks, and their morn-
ing BP and HR values were recorded. Within 4
weeks before and 6 months after treatment, all
the patients underwent UCG, 123I-MIBG imaging,
and 99mTc-MIBI SPECT. In addition to routine lab-
oratory examinations, their plasma NE levels, renin
activity, aldosterone and brain natriuretic pep-
tide (BNP) concentrations were measured in venous
blood.
Echocardiography
Before and after 6 months of treatment, UCG and an
analysis of its parameters were performed by inves-
tigators who had no knowledge of the study, using
an ultrasound system (SSD-6500; ALOKA Co., Ltd.,
Tokyo, Japan) with a sector transducer (frequencies
of 2.5 or 3.5MHz). Measurements of LV end-diastolic
diameter (LVDd), LV end-systolic diameter (LVDs),
IVSt and PWt at end diastole were recorded from M-
mode tracings according to the standard views and
1
O
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echniques. LVM was calculated using Devereux’s
ormula [24], and LVM index (LVMI) was obtained
y dividing the LVM by the body surface area.
VEF was calculated using the Teichholz method
25]. On the basis of the pulsed Doppler UCG stud-
es, the diastolic transmitral ﬂow determinants of
arly diastolic peak ﬂow velocity (E), late diastolic
eak ﬂow velocity (A), the ratio of E to A (E/A),
nd the deceleration time of E (Dct) were mea-
ured.
9mTc-MIBI SPECT study
o assess the effect of each drug on cardiac per-
ormance, especially LV diastolic function, patients
nderwent ECG-gated 99mTc-MIBI SPECT before and
months after treatment. Approximately 1110MBq
f 99mTc-MIBI (Daiich Radioisotope Laboratories,
td., Tokyo, Japan) was administered intravenously
nder resting conditions. SPECT image acquisition
as started after 30min with a 6-degree step and
60-degree rotation using a two-headed gamma
amera (E-CAM; Siemens Medical Solutions, Erlan-
en, Germany) equipped with a low-energy, high
esolution collimator. ECG-gated SPECT was per-
ormed with 32 frames per cardiac cycle. The
cquired data were processed on a medical image
rocessor (e. soft-P; Siemens Medical Solutions).
n data analysis, the standard algorithm of QGS
oftware (Cedars-Sinai Medical Center, Los Ange-
es, CA, USA), validated by Germano et al. [19,20],
as used to determine LV volumes. To estimate
V diastolic function, LV volume values from the
GS software were applied to a volume curve dif-
erentiation software (VCDiff; Daiich Radioisotope
aboratories, Ltd.). The LV time—volume curve was
lotted from each of the 32 frames, and was gen-
rated with Fourier transforms using 5 harmonics.
rom this volume curve and its ﬁrst differentiated
urve which was transformed into a LV time-ﬁlling
ate (dV/dt) curve, we obtained LV diastolic func-
ional parameters such as the peak ﬁlling rate
PFR), ﬁlling rate during the ﬁrst-third of diastole
1/3FR), and time to peak ﬁlling (TPF), in addition
o systolic variables such as end-systolic volume
ESV), end-diastolic volume (EDV) and LVEF. The PFR
as deﬁned as the greatest ﬁlling rate at early dias-
ole and corresponded to the ﬁrst maximum dV/dt
alue normalized to EDV, while the TPF was the
nterval from the time at end systole to that at the
FR (Fig. 1).23I-MIBG study
ur 123I-MIBG study was performed using an intra-
enous injection of 123I-MIBG (Daiich Radioisotope
Cardioprotective effect of an L/N-type Ca channel bloc
Figure 1 Example of a patient’s left ventricular (LV)
time—volume curve (top) and time-ﬁlling rate curve (bot-
tom) in 32-frame ECG-gated 99mTc-sestamibi SPECT. The
peak ﬁlling rate (PFR) is deﬁned as the greatest ﬁlling rate
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St early diastole and normalized to end-diastolic volume
EDV). The time to peak ﬁlling (TPF) is the time from end
ystole to PFR.
aboratories, Ltd.) at a dose of 111MBq with the
ubject fasted and resting. The interval between
ur 99mTc-MIBI and 123I-MIBG studies was 7 days.
10min static acquisition of the chest anterior
iew was performed using a three-headed gamma
C
m
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Table 1 Baseline clinical characteristics of patients.
Characteristics Cilnidipine (n = 16)
Age (years) 68± 5
Gender (M/F) 12/4
History of hypertension (years) 12± 5
Systolic BP (mmHg) 154± 17
Diastolic BP (mmHg) 85± 10
Heart rate (beats/min) 80± 9
Body mass index (kg/m2) 24± 2
Complications
Dyslipidemia, n (%) 6(37)
Diabetes mellitus, n (%) 2(13)
Hyperuricemia, n (%) 3(19)
Current medications
ACE inhibitors, n (%) 4(25)
ARBs, n (%) 6(38)
˛1 blockers, n (%) 3(19)
Diuretics, n (%) 1(6)
Values are expressed as mean± SD or number (%). BP, blood pres
receptor blocker.ker 265
amera with a low-energy, parallel hole collima-
or (MULTISPECT 3; Siemens Medical Solutions) at
5min (early imaging) and 4 h (delayed imaging)
fter the injection. Data processing was performed
sing a data processing system (ICON; Siemens Med-
cal Solutions). Neither attenuation correction nor
ecay correction for 123I half-life was performed.
V 123I-MIBG activity was measured with a manually
rawn region of interest (ROI) around the heart (H).
10× 10 pixel ROI was placed over the upper medi-
stinum area (M), and the heart to mediastinum
H/M) ratios at early and delayed imaging were
alculated from the mean counts per pixel. The
23I-MIBG washout rate (WR) in myocardium was
etermined as a percentage of the rate of decrease
n myocardial counts over time between early and
elayed imaging.
eurohumoral factors
fter each patient had rested in the supine position
or 15min before 123I-MIBG imaging, venous blood
amples were drawn from a catheter inserted into
he median cubital vein. Their plasma NE levels,
enin activity, aldosterone and BNP concentrations
ere measured.
tatistical analysisontinuous variables were expressed as
ean± standard deviation (SD) and categori-
al variables as a number (percentage). The data
ere processed using the GraphPad Prism version 4
Nifedipine retard (n = 16) P-value
67± 9 NS
11/5 NS
11± 9 NS
155± 12 NS
85± 11 NS
76± 11 NS
24± 3 NS
6(37) NS
2(13) NS
2(13) NS
3(19) NS
7(44) NS
5(31) NS
0(0) NS
sure; ACE, angiotensin-converting enzyme; ARB, angiotensin
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Table 2 Changes in blood pressure and heart rate.
Variable Baseline 3 months after 6 months after
Systolic BP (mmHg)
Cilnidipine 154 ± 17 140 ± 13* 131 ± 13*,†
Nifedipine retard 155 ± 12 143 ± 12* 137 ± 10*
Diastolic BP (mmHg)
Cilnidipine 85 ± 10 78 ± 9* 75 ± 7*
Nifedipine retard 85 ± 11 80 ± 8* 76 ± 9*
Heart rate (beats/min)
Cilnidipine 80 ± 9 74 ± 10** 72 ± 8**
Nifedipine retard 76 ± 11 73 ± 8 75 ± 9
Values are expressed as mean± SD. BP, blood pressure.
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i* P < 0.01 vs. baseline.
** P < 0.05 vs. baseline.
† P < 0.05 vs. 3 months after.
for Windows software package (GraphPad Software;
San Diego, CA, USA). Comparison of the mean val-
ues for the two groups was made using the Student’s
t-test. Multigroup comparisons of variables were
carried out by one-way ANOVA followed by Tukey’s
correction. Chi-square statistics were used for
categorical variables. The correlations between
the cardiac parameters by 99mTc-MIBI SPECT and
those by 123I-MIBG imaging were examined using
linear regression analysis. Probability values of
<0.05 were considered signiﬁcant.
Results
Baseline characteristics
There were no adverse reactions in either the cil-
nidipine or nifedipine retard group. All patients in
both groups completed the study. The ﬁnal dose
of each drug was 10.0± 4.5mg/day in the cilnidip-
ine group and 35.0± 8.9mg/day in the nifedipine
group. Baseline characteristics in each treatment
group are summarized in Table 1. Patients were
well matched for gender, age, BP, HR, body
mass index, complications, and current medica-
tions.
Blood pressure and heart rate
After 3 and 6 months of treatment, both systolic and
diastolic BPs signiﬁcantly decreased (p < 0.01 for
both) to similar extents in both groups. The changes
in BPs (systolic/diastolic) were 20.9/10.7mmHg in
the cilnidipine group and 18.9/10.6mmHg in the
nifedipine group after 6 months of treatment. HR
in the cilnidipine group was signiﬁcantly reduced
(p < 0.05) from baseline, whereas no signiﬁcant
(
f
1
f
shange in HR was found in the nifedipine group
uring the study period (Table 2).
chocardiography and neurohumoral factors
here were no signiﬁcant changes in LV wall thick-
ess (IVSt and PWt), LV diameter (LVDd and LVDs),
r LVEF in either group after treatment (data not
hown). Similarly, the E/A ratios, Dct and LVMI did
ot change in either group. In addition, no signif-
cant changes were found in biochemical data and
eurohumoral factors in the two groups at follow-up
Table 3).
adionuclide imaging
egarding parameters of LV systolic function; EDV,
SV, and LVEF seen with ECG-gated 99mTc-MIBI
PECT did not change in either group at follow-up.
s for LV diastolic function, after treatment with
ilnidipine, PFR and 1/3FR signiﬁcantly increased
p < 0.05 for both) while nifedipine retard did not
ffect these parameters. On the other hand, treat-
ent with either drug did not change TPF. Turning
ur attention to cardiac sympathetic activity evalu-
ted with 123I-MIBG imaging, the early and delayed
/M ratios also signiﬁcantly increased (p < 0.05 for
oth) in conjunction with a decreased WR (p < 0.05)
fter treatment with cilnidipine, but not with
ifedipine retard (Table 4). In the cilnidipine group,
signiﬁcant positive correlation was seen between
he rate of change in PFR and the rate of change
n early and delayed H/M ratios (p < 0.05 for both)
Fig. 2). Moreover, the same results were obtained
or the relationship between the rate of change in
/3FR and the rate of change in H/M ratios (p < 0.05
or both) (Fig. 3). However, no such relationship was
een in the nifedipine group.
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Figure 2 Relationship between the rate of change in peak ﬁlling rate (PFR) and the rate of change in heart to
mediastinum (H/M) ratios. A signiﬁcant positive correlation was seen between the rate of change in PFR and the rate
of change in early (A) and delayed (B) H/M ratios in the cilnidipine group. However, no such relationship was seen in
the nifedipine group (C and D).
Figure 3 Relationship between the rate of change in ﬁrst-third ﬁlling rate (1/3FR) and the rate of change in heart to
mediastunum (H/M) ratios. A signiﬁcant positive correlation was seen between the rate of change in 1/3FR and the
rate of change in early (A) and delayed (B) H/M ratios in the cilnidipine group. However, no such relationship was seen
in the nifedipine group (C and D).
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Table 3 Changes in echocardiographic variables and biochemical parameters.
Variable Baseline 6 months after P-value
E/A ratio
Cilnidipine 0.77 ± 0.14 0.78 ± 0.14 NS
Nifedipine retard 0.82 ± 0.25 0.80 ± 0.25 NS
Deceleration time (ms)
Cilnidipine 214.8 ± 46.5 198.2 ± 38.1 NS
Nifedipine retard 236.2 ± 77.3 223.1 ± 76.1 NS
LVMI (g/m2)
Cilnidipine 166.3 ± 38.3 157.6 ± 30.6 NS
Nifedipine retard 162.3 ± 27.8 158.4 ± 32.9 NS
Total cholesterol (mg/dl)
Cilnidipine 195.2 ± 29.7 193.3 ± 26.8 NS
Nifedipine retard 196.1 ± 37.4 194.7 ± 33.3 NS
Triglycerides (mg/dl)
Cilnidipine 137.8 ± 92.7 137.6 ± 94.4 NS
Nifedipine retard 139.3 ± 60.6 139.4 ± 70.5 NS
HDL-C (mg/dl)
Cilnidipine 48.9 ± 9.1 49.9 ± 8.8 NS
Nifedipine retard 48.5 ± 6.7 49.3 ± 9.7 NS
LDL-C (mg/dl)
Cilnidipine 110.3 ± 27.0 109.7 ± 25.4 NS
Nifedipine retard 112.5 ± 24.4 111.0 ± 23.9 NS
Fasting plasma glucose (mg/dl)
Cilnidipine 103.2 ± 15.2 103.7 ± 12.5 NS
Nifedipine retard 102.2 ± 10.6 104.3 ± 10.1 NS
HbA1c (%)
Cilnidipine 5.9 ± 1.1 5.8 ± 0.9 NS
Nifedipine retard 5.7 ± 1.0 5.8 ± 1.0 NS
Uric acid (mg/dl)
Cilnidipine 5.7 ± 1.3 5.7 ± 1.0 NS
Nifedipine retard 5.8 ± 1.3 5.7 ± 1.2 NS
Norepinephrine (pg/ml)1.0
Cilnidipine 670.7 ± 219.3 622.8 ± 188.5 NS
Nifedipine retard 621.8 ± 249.2 660.9 ± 227.0 NS
Plasma renin activity (ng/ml/h)
Cilnidipine 1.77 ± 1.95 2.58 ± 4.90 NS
Nifedipine retard 1.88 ± 2.16 2.50 ± 4.47 NS
Aldosterone (pg/ml)
Cilnidipine 93.9 ± 54.1 87.1 ± 37.7 NS
Nifedipine retard 92.6 ± 59.6 88.8 ± 54.7 NS
BNP (pg/ml)
Cilnidipine 48.5 ± 32.9 45.4 ± 34.7 NS
Nifedipine retard 44.1 ± 34.2 43.2 ± 32.3 NS
ow v
l; LDValues are expressed as mean± SD. E, early diastolic peak ﬂ
tricular mass index; HDL-C, high-density lipoprotein cholestero
hemoglobin; BNP, brain natriuretic peptide.Discussion
The major ﬁndings of the present study were
that cilnidipine signiﬁcantly improved LV diastolic
f
o
H
helocity; A, late diastolic peak ﬂow velocity; LVMI, left ven-
L-C, low-density lipoprotein cholesterol; HbA1c, glycosylatedunction and cardiac sympathetic activity, with-
ut an alteration in LV mass, in patients with
HD after 6 months of treatment. With similar
emodynamic and neurohumoral effects, cilnidip-
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Table 4 Changes in radionuclide imaging variables.
Variable Baseline 6 months after P-Value
EDV (ml)
Cilnidipine 89.9 ± 27.4 91.3 ± 23.8 NS
Nifedipine retard 89.0 ± 34.3 88.8 ± 28.7 NS
ESV (ml)
Cilnidipine 29.5 ± 14.8 28.2 ± 12.4 NS
Nifedipine retard 30.0 ± 15.4 27.6 ± 15.1 NS
LVEF(%)
Cilnidipine 68.2 ± 9.1 69.5 ± 8.0 NS
Nifedipine retard 70.0 ± 13.4 71.0 ± 11.4 NS
PFR (EDV/s)
Cilnidipine 2.46 ± 0.60 2.70 ± 0.58 0.026
Nifedipine retard 2.50 ± 0.61 2.58 ± 0.65 NS
1/3FR (EDV/s)
Cilnidipine 1.89 ± 0.58 2.28 ± 0.48 0.043
Nifedipine retard 1.90 ± 0.49 2.07 ± 0.42 NS
TPF (ms)
Cilnidipine 158.7 ± 46.6 169.6 ± 41.2 NS
Nifedipine retard 170.6 ± 22.6 174.2 ± 41.1 NS
Early H/M
Cilnidipine 2.39 ± 0.61 2.48 ± 0.58 0.024
Nifedipine retard 2.36 ± 0.54 2.40 ± 0.54 NS
Delayed H/M
Cilnidipine 2.43 ± 0.86 2.54 ± 0.86 0.028
Nifedipine retard 2.45 ± 0.82 2.48 ± 0.70 NS
Washout rate (%)
Cilnidipine 33.1 ± 14.9 30.4 ± 15.1 0.022
Nifedipine retard 33.0 ± 16.5 32.1 ± 14.7 NS
; ESV,
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H/M, heart to mediastinum ratio; PFR, peak ﬁlling rate; 1/3FR
ne showed signiﬁcant changes in many parameters
hrough radionuclide imaging, while nifedipine
etard did not. Although numerous clinical stud-
es have widely demonstrated the beneﬁcial effects
f cilnidipine in hypertensive patients on HR and
mbulatory BP [26], the white-coat-effect [27],
latelet function [28], and cardiac sympathetic
erve activity [29], there have been few reports
hat focused on LV diastolic function [15,16]. To the
est of our knowledge, this prospective study was
he ﬁrst to use indices from an ECG-gated SPECT
tudy in evaluating the effect of an antihyperten-
ive agent on LV diastolic function.
ssessment of LV diastolic functionCG examination has been widely used to study
ardiac performance in patients with heart dis-
ase, because it can be performed easily and
oninvasively at the bedside. Contrary to previous
r
S
i
cend-systolic volume; LVEF, left ventricular ejection fraction;
t-third ﬁlling rate; TPF, time to peak ﬁlling.
tudies [15,16], we could not see an improvement
n LV mass and diastolic function in either group
sing UCG parameters. Differences in background
actors might have been one cause for the dif-
erences in E/A ratio and Dct between our study
nd that of Takami and Shigematsu [16]. In the
tudy by Takami et al., all subjects were newly
iagnosed patients, and monotherapy groups were
ompared. In our study, only 7 patients in the cilni-
ipine group and 5 patients in the nifedipine group
eceived monotherapy. In addition, about 60% of
ur patients had already received ACE inhibitors
nd/or ARBs, suggesting that LV remodeling was
uppressed to a certain degree. Therefore, in our
tudy, minor changes in LV diastolic function might
ot have been accurately detected using conven-
ional pulsed Doppler UCG indices such as E/A
atio and Dct. We preferred to use ECG-gated
PECT because it has distinct advantages over UCG
n LV function quantiﬁcation; namely, data are
ollected over some hundreds of cardiac cycles,
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and operator-independent parameters are provided
almost automatically.
The maximum negative LV dP/dt and the time
constant of LV relaxation as measured by cardiac
catheterization are conventionally considered the
gold standards for assessing LV diastolic function,
but since cardiac catheterization is an invasive
examination, indices from ECG-gated radionuclide
ventriculography (RNV) have been used in clini-
cal settings [30]. As far as LV diastolic function is
concerned, recent studies have shown close rela-
tionships between RNV and SPECT indices such as
PFR, 1/3FR, and TPF [31,32]. Furthermore, these
diastolic function parameters derived from ECG-
gated SPECT have been shown to correlate well with
LV end-diastolic pressure at subsequent cardiac
catheterization [33]. Thus, compared to cardiac
catheterization, while limitations exist in the use of
ECG-gated SPECT, this modality is noninvasive and
useful for assessing LV diastolic function.
Improvement of cardiac sympathetic
activity
The present study demonstrated that cilnidipine
and nifedipine retard lowered blood pressure to
similar extent after 6 months of treatment. How-
ever, the effect on HR differed between these
two drugs in some respects: cilnidipine signiﬁcantly
reduced HR after treatment of 3 and 6 months,
and nifedipine retard did not. Since cilnidipine has
been shown to block N-type calcium channels in
sympathetic nerve terminals, leading to a suppres-
sion of NE release [12—14], this mechanism would
explain the difference in the effect on HR between
the two drugs. To assess and compare the direct
antisympathetic actions of cilnidipine and nifedip-
ine retard, we evaluated the effects of these drugs
on cardiac sympathetic activity using 123I-MIBG
imaging. While 123I-MIBG imaging has been widely
applied in patients with heart failure, there are
few reports that describe its usefulness in assess-
ing the effects on sympathetic nerve activity with
antihypertensive agents [9,29]. Common ﬁndings
demonstrated in these reports are a decreased H/M
ratio and an enhanced WR in hypertensive patients.
In the present study, cilnidipine improved param-
eters seen with 123I-MIBG imaging, as estimated
by an increase in H/M ratios and a reduction in
WR after treatment, suggesting that in contrast to
nifedipine retard, cilnidipine could modulate car-
diac sympathetic overactivity in patients with HHD.
Like cilnidipine, another CCB, azelnidipine, report-
edly suppresses the sympathetic nervous system.
The inhibitory mechanisms of azelnidipine on sym-
S
F
mT. Kosaka et al.
athetic nervous system seem to be different from
hose of cilnidipine. Unlike cilnidipine, azelnidipine
as been reported to suppress the cardiac sym-
athetic nervous system by directly acting on the
entral nervous system and improving baroreﬂex
ensitivity [34,35]. In comparison with cilnidipine,
e hope to investigate the cardioprotective effects
f azelnidipine on HHD in the future.
mprovement of LV diastolic function
onsidering data from the literature, our ﬁnding of
mproved LV diastolic function in concordance with
uppressed cardiac sympathetic overactivity using
ilnidipine treatment is in agreement with previous
tudies [15,16,29]. From results of the signiﬁ-
ant correlations between the parameters obtained
rom 99mTc-MIBI SPECT and 123I-MIBG imaging,
mproving cardiac sympathetic function appears to
e important in achieving the beneﬁcial effects of
ilnidipine on cardiac function. Our clinical study
oes not explain the underlying mechanisms leading
o the improvement of LV performance in patients
ith HHD, but it is speculated that the possible
eneﬁcial effects of cilnidipine may be due to the
odulated Ca2+ handling via the suppression of
ympathetic overactivity [36,37]. Cardiac myocyte
a2+ handling plays an important role in the regu-
ation of systolic and diastolic function. Diastolic
ysfunction results in part by a reduced expres-
ion of the sarcoplasmic reticulum Ca2+-ATPase 2
SERCA2); consequently the intracellular transient
a2+ is prolonged and relaxation is disturbed [38].
n evaluations of 123I-MIBG imaging in heart fail-
re patients, it was demonstrated that a reduced
/M ratio was related to the down-regulation of
ERCA2 mRNA expression [36]. Although there is no
vidence in any clinical study for direct interac-
ion between NE levels and gene transfer-mediated
timulation of SERCA2 activity, in terms of hyper-
ensive patients, we speculate that the decreased
E release into the synaptic cleft by blocking N-type
alcium channels with cilnidipine may contribute
o a relief of intracellular Ca2+ overload, leading
o improved LV diastolic function. It is suggested,
herefore, that the favorable effects of cilnidip-
ne on LV diastolic function may be related to not
nly calcium channel blocking activity, but also cal-
ium antagonism-independent modulation of gene
xpression in the arteries and myocardium, proba-
ly unrelated to blood pressure reduction.tudy limitations
irst, antihypertensive drugs other than the CCBs
ay have possibly inﬂuenced LV function in our
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[ardioprotective effect of an L/N-type Ca channel
tudy. Twenty of the 32 patients were already
eing given antihypertensive drugs, the dose of
hich, however, was not changed during the study
eriod, making any signiﬁcant contribution of those
rugs’ effects on LV function after CCB admin-
stration unlikely. Second, with regard to plasma
enin activity and aldosterone levels, since about
0% of patients in both groups were already tak-
ng ACE inhibitors and/or ARBs, we determined that
he effects of neurohumoral factors on LV function
ould not be assessed. Finally, we did not examine
issue Doppler UCG and tissue Doppler Tei index in
he present study. The parameters obtained from
hese modalities provide useful information about
lobal cardiac function [39,40], and LV diastolic
unction can be more accurately assessed in combi-
ation with the indices of ECG-gated SPECT. In the
uture, to establish the usefulness of gated SPECT
s a noninvasive standard method for evaluating
V diastolic function, we will need further studies
nrolling larger numbers of patients, and including
arious heart diseases.
onclusion
n contrast to nifedipine retard, cilnidipine signif-
cantly improved indices evaluated using radionu-
lide imaging, which reﬂect LV diastolic function
nd cardiac sympathetic activity. It is suggested
hat cilnidipine seems to improve LV diastolic func-
ion through its suppression of cardiac sympathetic
veractivity, via the blockade of N-type calcium
hannels in patients with HHD.
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